News
RARE faces regulatory setback as FDA issues a CRL for UX111, delaying approval of the MPS IIIA gene therapy until 2026.
Ultragenyx's high burn rate, costly R&D, and recent setbacks increase dilution risk, impacting future profitability. Learn ...
The decision follows the initial approval granted in September 2023, which covered patients aged five years and above.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results